{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:48:31Z","timestamp":1785473311238,"version":"3.56.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s12325-025-03137-3","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T08:36:04Z","timestamp":1744014964000},"page":"2728-2738","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Baseline Characteristics and Treatment Patterns of Patients with Atopic Dermatitis Treated with Oral Systemic Therapies: An Interim Analysis of the AD-REAL Study"],"prefix":"10.1007","volume":"42","author":[{"given":"Matthias","family":"Augustin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Serra-Baldrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Seneschal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Grond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Lampropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elrayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Ogwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"de la Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Bewley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"issue":"1","key":"3137_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","volume":"4","author":"S Weidinger","year":"2018","unstructured":"Weidinger S, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"3137_CR2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"3137_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.anai.2021.03.019","volume":"127","author":"R Chovatiya","year":"2021","unstructured":"Chovatiya R, et al. Clinical phenotyping of atopic dermatitis using combined itch and lesional severity: a prospective observational study. Ann Allergy Asthma Immunol. 2021;127(1):83\u201390 (e2).","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3137_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.644760","volume":"8","author":"FJ Legat","year":"2021","unstructured":"Legat FJ. Itch in atopic dermatitis\u2014What is new? Front Med (Lausanne). 2021;8: 644760.","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"3137_CR5","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3390\/jcm10061298","volume":"10","author":"M Talamonti","year":"2021","unstructured":"Talamonti M, et al. Quality of life and psychological impact in patients with atopic dermatitis. J Clin Med. 2021;10(6):1298.","journal-title":"J Clin Med"},{"issue":"1","key":"3137_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaip.2019.06.044","volume":"8","author":"AB Fishbein","year":"2020","unstructured":"Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection. J Allergy Clin Immunol Pract. 2020;8(1):91\u2013101.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"3137_CR7","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/jdv.18345","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409\u201331.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"3137_CR8","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1007\/s12325-023-02528-8","volume":"40","author":"JP Thyssen","year":"2023","unstructured":"Thyssen JP, et al. Baseline body surface area and itch severity define response to Baricitinib in patients with moderate-to-severe atopic dermatitis at week 16. Adv Ther. 2023;40(8):3574\u201387.","journal-title":"Adv Ther"},{"issue":"8","key":"3137_CR9","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.3390\/ijms21082671","volume":"21","author":"R Tamagawa-Mineoka","year":"2020","unstructured":"Tamagawa-Mineoka R, Katoh N. Atopic dermatitis: identification and management of complicating factors. Int J Mol Sci. 2020;21(8):2671.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3137_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s13555-021-00640-7","volume":"12","author":"JI Silverberg","year":"2022","unstructured":"Silverberg JI, et al. Clinical tailoring of baricitinib 2 mg in atopic dermatitis: baseline body surface area and rapid onset of action identifies response at week 16. Dermatol Ther (Heidelb). 2022;12(1):137\u201348.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"9","key":"3137_CR11","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/j.1468-3083.2012.04636.x","volume":"26","author":"J Ring","year":"2012","unstructured":"Ring J, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol. 2012;26(9):1176\u201393.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"3137_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40257-023-00837-w","volume":"25","author":"RW Kim","year":"2024","unstructured":"Kim RW, et al. Targeted systemic therapies for adults with atopic dermatitis: selecting from biologics and JAK inhibitors. Am J Clin Dermatol. 2024;25(2):179\u201393.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"3137_CR13","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis DMR, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43\u201356.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"3137_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s13555-021-00640-7","volume":"12","author":"JI Silverberg","year":"2022","unstructured":"Silverberg JI, et al. Clinical tailoring of baricitinib 2 mg in atopic dermatitis: baseline body surface area and rapid onset of action identifies response at week 16. Dermatology and Therapy. 2022;12(1):137\u201348.","journal-title":"Dermatology and Therapy"},{"key":"3137_CR15","unstructured":"Gesundheit BF. Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Arzneimittel-Richtlinie: Anlage XII \u2013 Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffennach \u00a7 35a des F\u00fcnften Buches Sozialgesetzbuch (SGB V) Baricitinib (neues Anwendungsgebiet: mittelschwere bis schwere atopische Dermatitis. 2021; Available from: https:\/\/www.bundesanzeiger.de\/pub\/de\/amtliche-veroeffentlichung?5."},{"issue":"3","key":"3137_CR16","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","volume":"145","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877\u201384.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"3137_CR17","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101\u201312.","journal-title":"N Engl J Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03137-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03137-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03137-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T08:00:06Z","timestamp":1747468806000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03137-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3137"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03137-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"8 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Matthias Augustin served as a consultant or paid speaker for clinical trials sponsored by companies that manufacture drugs used for the treatment of alopecia areata including AbbVie, Almirall, Eli Lilly and Company, and Pfizer and received support for attending meetings\/travel from Eli Lilly and Company. Anthony Bewley reports royalties from Practical Pyschodermatology (Wiley 2014); ad hoc consulting fees from AbbVie, Almirall, BMS, Eli Lilly and Company, Galderma, Incyte, Leo-Pharma, Janssen, Novartis, Pfizer, Sanofi, UCB; ad hoc lecturing fees from AbbVie, Almirall, BMS, Eli Lilly and Company, Galderma, Incyte, Leo-Pharma, Janssen, Novartis, Pfizer, Sanofi, UCB; support for attending meetings\/travel from Novartis, Galderma, UCB, Janssen, Sanofi and other financial or non-financial interests including Immediate Past President of ESDaP, Medical Advisory Board for National Eczema Society, Ichthyosis Support Group and Psoriasis Association. Julien Seneschal reports personal consulting fees from AbbVie, Almirall, Leo-Pharma, Eli Lilly and Company, Pfizer, La Roche Posay; honoraria from AbbVie, Almirall, Leo-Pharma, Eli Lilly and Company, Pfizer. Esther Seera-Baldrich reports payment\/honoraria from Amgen, Leo-Pharma, Sanofi, Eli Lilly and Company, Pfizer, Novartis, AbbVie, Incyte, Almirall and Galderma; support for attending meetings\/travel from Eli Lilly and Company, Sanofi, Pfizer, Novartis and Leo-Pharma. Andrew Pinter reports payment\/honoraria from Eli Lilly and Company; support for attending meetings and\/or travel from Eli Lilly and Company and participation on Data Safety Monitoring\/Advisory Boards from Eli Lilly and Company. Susanne Grond, Anastasia Lampropoulou, Mohamed Elrayes, Samuel Ogwu and Inmaculada De La Torre are employees and minor shareholders of Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Protocols for all studies included in this analysis were approved by the Institutional Review Board or Ethics Committee at each participating site. All studies included in this analysis were conducted in accordance with the ethical principles of the Declaration of Helsinki. Written informed consent was obtained from all eligible participants before undergoing study-related procedures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}